Skip to content
Open access

Structure based discovery of VMP-7 as a promising GlgE targeting lead against Mycobacterium tuberculosis

Sep 2026 · Frontiers in Microbiology · Vol 17 · 0 citations · 24 references
Medicine

TL;DR

Findings validate GlgE as a highly conserved target and identify VMP-7 as a promising lead candidate for further preclinical development of novel anti-TB therapeutics.

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis (M.tb), remains a major global health challenge, necessitating the identification of novel drug targets with high specificity and therapeutic potential. Maltosyltransferase (GlgE) is a critical enzyme in the biosynthesis of cytosolic α-glucan, a key component required for maintaining cell wall integrity and intracellular survival of the pathogen. GlgE catalyzes the transfer of maltosyl units from maltose-1-phosphate to elongating α-glucan chains, and its inactivation results in toxic accumulation of metabolic intermediates, ultimately leading to bacterial death. Importantly, the absence of homologous pathways in humans underscores its suitability as a selective anti-tubercular (anti-TB) target. Sequence analysis of 382 clinical isolates demonstrated complete conservation of the glgE gene, highlighting its evolutionary stability and essentiality. Subsequently, structure-based virtual screening followed by molecular fingerprint clustering was performed to identify chemically diverse inhibitors. Twelve top ranked compounds (VMP-1 to VMP-12) were further evaluated through in-vitro antimycobacterial assays in broth culture and infected THP-1 derived macrophages, along with cytotoxicity assessment. Among these, VMP-7 exhibited significant inhibitory activity against M.tb at 12.5 μg/mL, with minimal cytotoxic effects on host cells. Collectively, these findings validate GlgE as a highly conserved target and identify VMP-7 as a promising lead candidate for further preclinical development of novel anti-TB therapeutics.

Read PDF

Similar papers

2025

In-Silico Identification of MurX as a Novel Drug Target in Mycobacterium tuberculosis and Molecular Docking Analysis of Bergenin

Findings support MurX as a viable therapeutic target and Bergenin as a promising candidate for further anti-TB drug development, and lays the foundation for subsequent experimental validation and the design of novel therapeutics targeting resistant strains of Mtb.

Mohd Asif Siddiqui, Ravindra Kumar Jain, Abhilash Sharma · 0 citations
Open access Sep 2026

In silico assessment of natural compounds against mycobacterium tuberculosis Rv1509 protein

Tuberculosis (TB) remains a leading cause of mortality globally, driven by the infectious pathogen, Mycobacterium tuberculosis (M.tb). A novel DNA methyltransferase (DNA MTase), encoded by the Rv1509 gene and involved in TB pathogenesis, has been identified as a promising therapeutic target of anti-TB drugs. The presen...

Haleema Fayaz, Waseem Ali, Gauri Shrivastava et al. · 0 citations
Open access Sep 2026

Exploration of novel anti-TB agents targeting the serine/threonine kinase enzyme (PknE) in Mycobacterium tuberculosis: an in silico study

A structure-based in silico workflow comprising virtual screening of 2,202 FDA-approved compounds, molecular docking, molecular docking, 300 ns molecular dynamics simulation, and in silico toxicity profiling provide a strong computational basis for repurposing these agents as adjunct anti-TB therapies, pending experime...

Abdallah Elssir Ahmed, Reem M. A. Ebrahim, N. M. Hajhamed et al. · 0 citations
Open access Sep 2026

Computational evaluation of novel Schiff base compounds targeting Mycobacterium tuberculosis

Background/Aim Tuberculosis remains a major global health concern and continues to pose significant challenges to global public health. Key enzymes involved in mycobacterial cell wall biosynthesis, including DprE1, InhA, KasA, MmpL3, and LdtMt2, represent attractive therapeutic targets for anti-tubercular drug discover...

Akshata S. Menasinakai, P. Ronad, A. V. Viswanatha Swamy · 0 citations
Sep 2026

Inhibition of Mycobacterium tuberculosis β-Lactamase BlaC with Natural Products: An Integrated Computational Study

Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains the second leading cause of infectious disease-related mortality worldwide. Resistance to β-lactam antibiotics is largely attributed to the chromosomally encoded BlaC β-lactamase, which hydrolyzes commonly used β-lactam drugs. Although inhibitors such...

S. Sreekumar, Bhagya Jyothi J. L, Liji Selvanose et al. · 0 citations
Review Sep 2026

TrmD: A Promising Antibacterial Target and Its Small-Molecule Inhibitors.

Bacterial tRNA-(N1G37) methyltransferase (TrmD), a member of the SPOUT superfamily, plays a pivotal role in catalyzing the methyl group transfer from S-adenosyl-l-methionine to the N1 position of G37 in the pathway of post-transcriptional modifications of bacterial tRNA. In response to the urgent global clinical need t...

Zhi-Wei Meng, Dian-Fu Xia, Xin-Tong Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.